$NKTR
NEKTAR THERAPEUTICS

2016 Q3 Form 10-Q Financial Statement

#000156459016022647 Filed on August 04, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $36.34M $32.77M $22.66M
YoY Change -39.39% 44.6% -20.52%
Cost Of Revenue $7.033M $7.708M $10.53M
YoY Change 4.04% -26.83% 106.23%
Gross Profit $29.30M $25.06M $12.13M
YoY Change -44.91% 106.65% -48.19%
Gross Profit Margin 80.64% 76.48% 53.51%
Selling, General & Admin $10.30M $11.00M $10.20M
YoY Change 8.42% 7.84% 6.25%
% of Gross Profit 35.15% 43.89% 84.11%
Research & Development $51.95M $52.35M $45.41M
YoY Change 20.18% 15.28% 23.73%
% of Gross Profit 177.29% 208.9% 374.47%
Depreciation & Amortization $3.900M $3.900M $2.800M
YoY Change 18.18% 39.29% -12.5%
% of Gross Profit 13.31% 15.56% 23.09%
Operating Expenses $51.95M $52.35M $45.41M
YoY Change 20.18% 15.28% 23.73%
Operating Profit -$32.90M -$38.33M -$43.47M
YoY Change -7952.27% -11.83% 89.69%
Interest Expense -$10.20M $5.627M $4.118M
YoY Change -342.74% 36.64% -8.24%
% of Operating Profit
Other Income/Expense, Net -$10.15M -$9.024M
YoY Change 12.49% -5.27%
Pretax Income -$43.10M -$48.48M -$52.49M
YoY Change 431.38% -7.65% 61.81%
Income Tax $100.0K $127.0K $164.0K
% Of Pretax Income
Net Earnings -$43.22M -$48.60M -$52.66M
YoY Change 426.93% -7.7% 61.34%
Net Earnings / Revenue -118.96% -148.32% -232.37%
Basic Earnings Per Share -$0.32 -$0.36 -$0.40
Diluted Earnings Per Share -$0.32 -$0.36 -$0.40
COMMON SHARES
Basic Shares Outstanding 136.7M 131.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $253.5M $274.9M $254.7M
YoY Change -5.34% 7.93% -7.85%
Cash & Equivalents $63.30M $55.68M $20.88M
Short-Term Investments $190.2M $219.2M $233.8M
Other Short-Term Assets $4.000M $5.427M $8.782M
YoY Change -23.28% -38.2% 89.72%
Inventory $10.80M $10.26M $10.12M
Prepaid Expenses
Receivables $14.20M $27.78M $3.680M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $282.5M $318.3M $302.2M
YoY Change -1.34% 5.32% 1.35%
LONG-TERM ASSETS
Property, Plant & Equipment $65.60M $67.77M $72.16M
YoY Change -9.56% -6.08% 1.53%
Goodwill $76.50M $76.50M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $504.0K $5.762M
YoY Change -96.39% -91.25% -21.53%
Total Long-Term Assets $142.6M $144.8M $154.4M
YoY Change -12.46% -6.24% -14.17%
TOTAL ASSETS
Total Short-Term Assets $282.5M $318.3M $302.2M
Total Long-Term Assets $142.6M $144.8M $154.4M
Total Assets $425.1M $463.1M $456.7M
YoY Change -5.37% 1.41% -4.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.100M $2.328M $2.833M
YoY Change 211.54% -17.83% -61.91%
Accrued Expenses $37.60M $37.00M $36.40M
YoY Change -13.76% 1.65% 526.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.400M $3.600M $5.600M
YoY Change -59.32% -35.71%
Total Short-Term Liabilities $76.30M $79.28M $81.08M
YoY Change -63.33% -2.21% -3.89%
LONG-TERM LIABILITIES
Long-Term Debt $245.1M $245.3M $127.9M
YoY Change 18753.85% 91.79% -36.37%
Other Long-Term Liabilities $171.5M $6.020M $16.67M
YoY Change 1507.01% -63.88% -6.19%
Total Long-Term Liabilities $416.6M $6.020M $16.67M
YoY Change 3803.67% -63.88% -6.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $76.30M $79.28M $81.08M
Total Long-Term Liabilities $416.6M $6.020M $16.67M
Total Liabilities $492.9M $502.4M $421.6M
YoY Change 20.16% 19.16% -17.9%
SHAREHOLDERS EQUITY
Retained Earnings -$1.936B -$1.805B
YoY Change 7.23% -0.34%
Common Stock $1.898B $1.842B
YoY Change 3.07% 3.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$67.90M -$39.25M $35.10M
YoY Change
Total Liabilities & Shareholders Equity $425.1M $463.1M $456.7M
YoY Change -5.37% 1.41% -4.49%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$43.22M -$48.60M -$52.66M
YoY Change 426.93% -7.7% 61.34%
Depreciation, Depletion And Amortization $3.900M $3.900M $2.800M
YoY Change 18.18% 39.29% -12.5%
Cash From Operating Activities -$27.30M -$13.70M -$47.20M
YoY Change 93.62% -70.97% 418.68%
INVESTING ACTIVITIES
Capital Expenditures -$500.0K -$1.500M -$3.500M
YoY Change -87.8% -57.14% 400.0%
Acquisitions
YoY Change
Other Investing Activities $28.80M -$3.300M -$62.50M
YoY Change 190.91% -94.72% -1141.67%
Cash From Investing Activities $28.40M -$4.900M -$66.00M
YoY Change 398.25% -92.58% -1345.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.600M 1.700M 4.700M
YoY Change 3.13% -63.83% 135.0%
NET CHANGE
Cash From Operating Activities -27.30M -13.70M -47.20M
Cash From Investing Activities 28.40M -4.900M -66.00M
Cash From Financing Activities 6.600M 1.700M 4.700M
Net Change In Cash 7.700M -16.90M -108.5M
YoY Change -485.0% -84.42% 5927.78%
FREE CASH FLOW
Cash From Operating Activities -$27.30M -$13.70M -$47.20M
Capital Expenditures -$500.0K -$1.500M -$3.500M
Free Cash Flow -$26.80M -$12.20M -$43.70M
YoY Change 168.0% -72.08% 420.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
136732450
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55676000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55570000
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
253374000
CY2016Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
219178000
CY2016Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27777000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19947000
CY2016Q2 us-gaap Inventory Net
InventoryNet
10262000
CY2015Q4 us-gaap Inventory Net
InventoryNet
11346000
CY2016Q2 us-gaap Other Assets Current
OtherAssetsCurrent
5427000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
9814000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
350051000
dei Document Type
DocumentType
10-Q
CY2016Q2 us-gaap Assets Current
AssetsCurrent
318320000
CY2016Q2 us-gaap Goodwill
Goodwill
76501000
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
504000
CY2016Q2 us-gaap Assets
Assets
463099000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2328000
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12463000
CY2016Q2 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
13470000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6919000
CY2016Q2 us-gaap Interest Payable Current
InterestPayableCurrent
4144000
CY2016Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3616000
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Trading Symbol
TradingSymbol
NKTR
dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000906709
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67774000
CY2016Q2 nktr Liability For Refundable Upfront Payment
LiabilityForRefundableUpfrontPayment
12500000
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
16015000
CY2016Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7827000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
79282000
CY2016Q2 us-gaap Senior Long Term Notes
SeniorLongTermNotes
242567000
CY2016Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
2756000
CY2016Q2 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
111590000
us-gaap Revenues
Revenues
131462000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
136350000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12627000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7634000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1260000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7830000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1084000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4637000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
17000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
6465000
nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
5250000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2831000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-54000
nktr Increase Decrease In Upfront Payment Liabilities
IncreaseDecreaseInUpfrontPaymentLiabilities
12500000
nktr Increase Decrease In Upfront Payment Liabilities
IncreaseDecreaseInUpfrontPaymentLiabilities
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7704000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4434000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-725000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-37252000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
72806000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
107363000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5215000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3234000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4584000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
31323000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12836000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
3517000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2484000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
9643000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
7798000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6126000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5314000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-91000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-25000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
106000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8510000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2019000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2170000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
498642000
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1935587000
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
-39251000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
6429000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q2 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2015Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
60135000
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
12867000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
62426000
CY2015Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
10968000
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6020000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9740000
CY2016Q2 us-gaap Liabilities
Liabilities
502350000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
13000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1898342000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
463099000
CY2015Q4 us-gaap Liabilities
Liabilities
492213000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1876072000
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20487000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
246000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10151000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1333000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9024000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
127000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
10202000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
457000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48476000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52493000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
18978000
us-gaap Royalty Revenue
RoyaltyRevenue
870000
nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
42457000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
8702000
nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
102948000
us-gaap Revenues
Revenues
91649000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
26966000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
14650000
us-gaap Royalty Revenue
RoyaltyRevenue
7576000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
18942000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21262000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
92423000
us-gaap Interest Expense
InterestExpense
11304000
us-gaap Costs And Expenses
CostsAndExpenses
131888000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47809000
us-gaap Operating Income Loss
OperatingIncomeLoss
-426000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
10027000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
294000
us-gaap Net Income Loss
NetIncomeLoss
-68101000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18034000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67807000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18460000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
377000
us-gaap Net Income Loss
NetIncomeLoss
-18837000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
136072000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
131502000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18768000
us-gaap Interest Expense
InterestExpense
8289000
CY2015Q2 us-gaap Costs And Expenses
CostsAndExpenses
66130000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38325000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
458000
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7708000
CY2015Q2 us-gaap Revenues
Revenues
22661000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52350000
CY2015Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
10534000
CY2016Q2 us-gaap Costs And Expenses
CostsAndExpenses
71093000
CY2016Q2 us-gaap Revenues
Revenues
32768000
CY2015Q2 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
6208000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67950000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48787000
us-gaap Costs And Expenses
CostsAndExpenses
139458000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43469000
CY2016Q2 us-gaap Royalty Revenue
RoyaltyRevenue
3516000
CY2016Q2 us-gaap Interest Expense
InterestExpense
5627000
CY2016Q2 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
4982000
CY2015Q2 us-gaap Interest Expense
InterestExpense
4118000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
164000
CY2015Q2 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
5152000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-48603000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-52657000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101618000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10184000
CY2015Q2 us-gaap Royalty Revenue
RoyaltyRevenue
745000
CY2016Q2 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
8270000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11035000
CY2016Q2 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
8115000
CY2015Q2 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
4740000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
16578000
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
136602000
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
136602000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19998000
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
135289000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
135289000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45412000
CY2015Q4 us-gaap Goodwill
Goodwill
76501000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
754000
CY2015Q4 us-gaap Assets
Assets
498642000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2363000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5998000
CY2015Q4 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
8220000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4156000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4198000
CY2015Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
4756000
CY2015Q4 nktr Liability For Refundable Upfront Payment
LiabilityForRefundableUpfrontPayment
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9737000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71336000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21428000
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10127000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
61246000
CY2015Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
241699000
CY2015Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
1073000
CY2015Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
116029000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1867486000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
131643000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52879000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5833000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
621000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
73000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2828000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-190000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
5075000
nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
1238000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1859000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
11772000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
16057000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
124468000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
111001000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12365000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20875000
us-gaap Interest Paid
InterestPaid
10448000
us-gaap Interest Paid
InterestPaid
8320000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to estimated selling prices of deliverables in collaboration agreements, estimated periods of performance, the net realizable value of inventory, the impairment of investments, the impairment of goodwill and long-lived assets, contingencies, accrued clinical trial expenses, estimated non-cash royalty revenue and interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, estimates are assessed each period and updated to reflect current information and any changes in estimates will generally be reflected in the period first identified.</p></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation, including as a result of the adoption of new accounting guidance related to debt issuance costs described below.&nbsp;&nbsp;Such reclassifications do not materially impact previously reported revenue, operating income (loss), net income (loss), total assets, liabilities or stockholders&#8217; equity (deficit). </p></div>
CY2016Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
274854000
CY2016Q2 us-gaap Senior Notes
SeniorNotes
250000000
CY2016Q2 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
256400000
CY2016Q2 us-gaap Capital Lease Obligations
CapitalLeaseObligations
6400000
nktr Number Of Operating Business Segment
NumberOfOperatingBusinessSegment
1
CY2015Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
308944000
nktr Debt Investment Maximum Maturity Period
DebtInvestmentMaximumMaturityPeriod
Two years or less
nktr Debt Investment Maturity Date Description
DebtInvestmentMaturityDateDescription
One year or less
CY2016Q2 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2015Q2 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2016Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
216248000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
250444000
CY2016Q2 nktr Cash And Restricted Cash
CashAndRestrictedCash
1044000
CY2015Q4 nktr Cash And Restricted Cash
CashAndRestrictedCash
1842000
CY2016Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2015Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2015Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2630000
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3236000
CY2016Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6632000
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6087000
CY2016Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1000000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2023000
nktr Estimated Annual Interest Rate On Royalty Liability
EstimatedAnnualInterestRateOnRoyaltyLiability
0.17
nktr Royalty Agreement Contingent Payment Description
RoyaltyAgreementContingentPaymentDescription
as a result of worldwide net sales of MIRCERA® for the 12 month periods ended December 31, 2013 and 2012 not reaching certain minimum thresholds.
CY2015Q3 nktr Damage Claim For Alleged Unpaid Licensing Fee
DamageClaimForAllegedUnpaidLicensingFee
1500000
nktr Potential Development Milestones
PotentialDevelopmentMilestones
147000000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6264000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4560000
CY2016Q2 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
451391
CY2015Q2 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
733952
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
1313937
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
969250

Files In Submission

Name View Source Status
0001564590-16-022647-index-headers.html Edgar Link pending
0001564590-16-022647-index.html Edgar Link pending
0001564590-16-022647.txt Edgar Link pending
0001564590-16-022647-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gbljdgkle2s3000001.jpg Edgar Link pending
gbljdgkle2s3000002.jpg Edgar Link pending
nktr-10q_20160630.htm Edgar Link pending
nktr-20160630.xml Edgar Link completed
nktr-20160630.xsd Edgar Link pending
nktr-20160630_cal.xml Edgar Link unprocessable
nktr-20160630_def.xml Edgar Link unprocessable
nktr-20160630_lab.xml Edgar Link unprocessable
nktr-20160630_pre.xml Edgar Link unprocessable
nktr-ex101_193.htm Edgar Link pending
nktr-ex311_8.htm Edgar Link pending
nktr-ex312_6.htm Edgar Link pending
nktr-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending